The subject matter described herein relates generally to the dispensation of pharmaceuticals and more specifically to a tracking system for the delivery of medication.
Patient-controlled analgesia pumps may provide patients direct control over the delivery of some medications including, for example, opioid pain medications, which are otherwise administered in single doses by medical professionals via intramuscular injections or intravenous injection. A patient-controlled analgesia pump is a computerized pump that houses a reservoir of multiple doses of a medication and is connected directly to a patient's vein. The patient-controlled analgesia pump may be configured to deliver a constant flow of the medication to the patient. Alternatively and/or additionally, the patient-controlled analgesia pump may allow the patient to self-administer individual doses of the medication on an as-needed basis.
Systems, methods, and articles of manufacture, including computer program products, are provided for tracking dose pattern at a patient-controlled analgesic pump and patient response. For example, the patient-controlled analgesic pump may be communicatively coupled with a tracking engine configured to track a quantity and/or frequency of attempts to trigger the delivery of a dose of medication, the delivery of a dose of medication to a patient, and/or the denial of the delivery of a dose of medication to a patient. The tracking engine may be further configured to track the patient's vital signs including, for example, respiratory rate, oxygen saturation, heart rate, pain level, motor movement, and/or the like. The tracking engine may determine a correlation between the dose pattern observed at the patient-controlled analgesic pump and the patient's response. Moreover, the tracking engine may generate electronic alerts when one or more anomalies are detected in the dose pattern observed at the patient-controlled analgesic pump and/or the patient's vital signs.
According to some aspects, a method may include determining, based at least on one or more dose events at a pump configured to deliver a medication to a patient, a dose pattern for delivering the medication to the patient. The method may also include receiving, from a patient monitor, one or more vital signs associated with the patient. The method may further include determining, based at least on the dose pattern at the pump and the one or more vital signs of the patient, a presence of one or more anomalies. The method may also include sending, to a mobile device, an electronic alert in response to determining the presence of the one or more anomalies.
In some aspects, the one or more dose events may include an attempt by the patient to trigger a delivery of a dose of the medication, the delivery of the dose of the medication, and/or a denial of the delivery of the dose of the medication.
In some aspects, the one or more vital signs include a respiratory rate, an oxygen saturation, a heart rate, a pain level, and/or a motor movement.
In some aspects, the method further includes adjusting, based at least on the dose pattern at the pump and/or the one or more vital signs of the patient, the dose pattern at the pump. In some aspects, the dose pattern is adjusted by at least modifying a quantity and/or frequency of one or more doses of medication delivered to and/or denied from the patient. In some aspects, the dose pattern is adjusted by at least modifying a duration of an active period, an inactive period, and/or a lockout period at the pump. In some aspects, the dose pattern is adjusted by at least modifying a maintenance dose at the pump.
In some aspects, the one or more anomalies may include a volume of the medication delivered to the patient being greater than a maximum threshold value or less than a minimum threshold value. In some aspects, the one or more anomalies include the one or more vital signs of the patient being greater than a maximum threshold value or less than a minimum threshold value.
In some aspects, the patient monitor includes one or more sensors configured to measure the one or more vital signs of the patient. The one or more sensors may include at least one motion sensor. The presence of the one or more anomalies may be determined based on motion data measured by the at least one motion sensor.
Implementations of the current subject matter can include methods consistent with the descriptions provided herein as well as articles that comprise a tangibly embodied machine-readable medium operable to cause one or more machines (e.g., computers, etc.) to result in operations implementing one or more of the described features. Similarly, computer systems are also described that may include one or more processors and one or more memories coupled to the one or more processors. A memory, which can include a non-transitory computer-readable or machine-readable storage medium, may include, encode, store, or the like one or more programs that cause one or more processors to perform one or more of the operations described herein. Computer implemented methods consistent with one or more implementations of the current subject matter can be implemented by one or more data processors residing in a single computing system or multiple computing systems. Such multiple computing systems can be connected and can exchange data and/or commands or other instructions or the like via one or more connections, including, for example, to a connection over a network (e.g. the Internet, a wireless wide area network, a local area network, a wide area network, a wired network, or the like), via a direct connection between one or more of the multiple computing systems, etc.
The details of one or more variations of the subject matter described herein are set forth in the accompanying drawings and the description below. Other features and advantages of the subject matter described herein will be apparent from the description and drawings, and from the claims. While certain features of the currently disclosed subject matter are described for illustrative purposes in relation to the tracking of dose pattern and patient responses, it should be readily understood that such features are not intended to be limiting. The claims that follow this disclosure are intended to define the scope of the protected subject matter.
The accompanying drawings, which are incorporated in and constitute a part of this specification, show certain aspects of the subject matter disclosed herein and, together with the description, help explain some of the principles associated with the disclosed implementations. In the drawings,
When practical, similar reference numbers denote similar structures, features, or elements.
A patient-controlled analgesic pump may allow a patient to directly control the delivery of a medication instead of having to rely on medical professionals to administer the opioid pain medication via intramuscular injections or intravenous injections. For example, the patient-controlled analgesic pump may deliver, to the patient, one or more doses of the medication in response to the patient pressing a button on a handset coupled with the patient-controlled analgesic pump. To ensure timely, effective, and safe patient care, the use of patient-controlled analgesic pumps for delivering medication may still require frequent oversight from medical professionals. This may be especially true when a patient-controlled analgesic pump is being used to deliver controlled substances, such as opioid pain medications, that are susceptible to abuse and diversion and could cause adverse effects such as over sedation and low respiratory rate, loss of motor function, and/or apnea. As such, in some example embodiments, a tracking engine may be configured to track the doses of a medication delivered to and/or denied from/for a patient and the corresponding responses (e.g., vital signs) from the patient. For instance, the tracking engine may track the quantity of doses of the medication that was attempted by, delivered to, and/or, denied for the patient, the rate at which the doses of the medication were attempted by, delivered to, and/or, denied for the patient, as well as the patient's vital signs including, for example, respiratory rate, oxygen saturation, heart rate, pain level, motor movement (e.g., leg movement), and/or the like.
The pump 120 may be a patient-controlled analgesic (PCA) pump configured to deliver a medication to a patient 140. However, it should be appreciated that the pump 120 may be any infusion system configured to deliver a substance (e.g., fluid, nutrients, medication, and/or the like) to a patient's circulatory system or epidural space via, for example, intravenous infusion, subcutaneous infusion, arterial infusion, epidural infusion, and/or the like. Alternatively, the infusion system may be configured to deliver a substance (e.g., fluid, nutrients, medication, and/or the like) to the patient's digestive system via a nasogastric tube (NG), a percutaneous endoscopic gastrostomy tube (PEG), a nasojejunal tube (NJ), and/or the like. The pump 120 may be configured to receive one or more syringes containing a medication such as, for example, an opioid pain medication (e.g., morphine, hydromorphone, fentanyl, and/or the like). Moreover, the pump 120 may deliver, to the patient 140, the medication in one or more doses including, for example, patient demand doses, clinician doses, loading doses, and/or maintenance doses. For instance, the patient 140 may trigger the delivery of a patient demand dose by at least pressing a button in a handset coupled with the pump 120. Additionally and/or alternatively, the patient-controlled analgesic pump may deliver, to the patient, one or more doses of the medication at set time intervals. In some implementations, the pump 120 may be used in an at-home setting, a clinical setting, in a convalescent care environment, and/or the like.
The pump 120 may include a dose controller 125 configured to detect one or more dose events at the pump 120 including, for example, the patient 140 attempting to trigger the delivery of a dose of medication, the delivery of a dose of medication to the patient 140, the denial of the delivery of a dose of medication to the patient 140, and/or the like. The dose controller 125 may report, to the tracking engine 110, the one or more dose events detected at the pump 120. In some example embodiments, the tracking engine 110 may determine, based at least on the one or more dose events reported by the dose controller 125, a dose pattern at the pump 120. For instance, the tracking engine 110 may determine a quantity and/or frequency of attempts to trigger the delivery of a dose of medication, the delivery of a dose of medication to the patient 140 (e.g., in response to an attempt to trigger the delivery of a dose of medication or at a set time interval), and/or the denial of the delivery of a dose of medication to the patient 140. As used herein, an attempt to trigger the delivery of a dose of medication may refer to a request by the patient 140 for the pump 120 to deliver a dose of medication, for example, by pressing a button on a handset coupled with the pump 120. Meanwhile, the denial of the delivery of a dose of medication may refer to the pump 120 preventing a dose of medication from being delivered to the patient 140 despite the patient 140 requesting the delivery of a dose of medication. The patient 140 may be denied the delivery of a dose of medication during a lockout period at the pump 120. For example, the delivery of one or more doses of medication to the patient 140 may trigger a subsequent lockout period at the pump 120 in order to prevent an excess of volume through frequency of the doses of medication from being delivered to the patient 140.
Referring again to
According to some example embodiments, the tracking engine 110 may be configured to track the one or more vital signs associated with the patient 140 along with the corresponding dose pattern observed at the pump 120. The tracking engine 110 may correlate the one or more vital signs associated with the patient 140 with the dose pattern observed at the pump 120. For example, the tracking engine 110 may determine the respiratory rate, oxygen saturation, carbon dioxide concentration, heart rate, motor movement, pain level, and/or rate of change of vital sign of the patient 140 when the patient 140 is subject to a certain dose pattern. As noted, the dose pattern observed at the pump 120 may include the quantity and/or frequency of attempts to trigger the delivery of a dose of medication, the delivery of a dose of medication to the patient 140, and/or the denial of the delivery of a dose of medication to the patient 140.
In some example embodiments, the tracking engine 110 may be configured to adjust, based on the dose pattern observed at the pump 120 and/or the vital signs of the patient 140 reported by the patient monitor 130, the dose pattern at the pump 120. The dose pattern at the pump 120 may be adjusted by at least modifying the quantity and/or frequency of the doses of medication delivered to the patient 140.
In some example embodiments, the tracking engine 110 may adjust the dose pattern at the pump 120 by at least changing a duration of an active period, an inactive period, and/or a lockout period at the pump 120. The active period may occur when the medication is being delivered to the patient 140. The inactive period may occur when the medication is not being delivered to the patient 140, but the medication is not prevented from being delivered to the patient 140 (e.g., during the lockout period). Increasing the duration of the active period at the pump 120 and/or decreasing the duration of the inactive period and/or lockout period at the pump 120 may result in an increase in the volume of medication delivered to the patient 140. Alternatively and/or additionally, the tracking engine 110 may adjust the dose pattern at the pump 120 by at least modifying a maintenance dose at the pump 120. For example, the tracking engine 110 may adjust the dose pattern at the pump 120 by adjusting the maximum dose limit associated with a given time period (e.g., one hour or a different time period) to increase or decrease the quantity of medication delivered to the patient during that time period. The tracking engine 110 may also adjust the dose pattern at the pump 120 by discontinuing the delivery of medication to the patient.
As used herein, a maintenance dose may refer to a minimum volume of medication administered continuously to the patient 140. Accordingly, modifying the maintenance dose at the pump 120 may trigger a corresponding change in the quantity and/or frequency of the doses of medication delivered to and/or denied from the patient 140.
In some example embodiments, the tracking engine 110 may also be configured to generate one or more electronic alerts based on the dose pattern observed at the pump 120 and/or the vital signs of the patient 140 reported by the patient monitor 130. The one or more electronic alerts may include wireless alert messages such as, for example, push notifications, short messaging service (SMS) message, and/or the like. Furthermore, the one or more electronic alerts may include an indication of a type of anomaly occurring in the dose pattern observed at the pump 120 and/or the vital signs of the patient 140 reported by the patient monitor 130. The anomaly may include, for example, end-tidal CO2 (ETCO2) too high, no breath, low respiratory rate, quantity of denied patient demand doses exceeds limit, rate of change of vital sign exceeds a limit, a value of a vital sign exceeds a limit, high heart rate, quantity of patient demand doses with no or limited improvement in pain level, and/or the like. Alternatively and/or additionally, the one or more electronic alerts may include a patient identifier, a medication identifier, and/or a quantity of medication delivered to the patient. For instance, the one or more electronic alerts may specify the volume of medication, the quantity of doses, the rate of delivered doses, and/or the type of doses (e.g., patient demand doses, clinician doses, loading doses, maintenance doses, and/or the like) delivered to the patient.
For example, the tracking engine 110 may detect the presence of one or more anomalies in the dose pattern observed at the pump 120 and/or the vital signs of the patient 140 reported by the patient monitor 130. The one or more anomalies may include the volume of medication delivered to the patient 140 being greater than or equal to a maximum threshold value and/or less than or equal to a minimum threshold value. Alternatively and/or additionally, the one or more anomalies may include one or more vital signs of the patient 140 being greater than or equal to a maximum threshold value and/or less than or equal to a minimum threshold value. Alternatively and/or additionally, the one or more anomalies may include a rate of change in one or more vital signs of the patient 140 being greater than or equal to a maximum threshold value and/or less than or equal to a minimum threshold value. Alternatively and/or additionally, the one or more anomalies may include a quantity of medication delivered to the patient 140 with no or limited improvement in pain level being greater than or equal to a maximum threshold value and/or less than or equal to a minimum threshold value. The threshold values may be patient-specific (e.g., a predetermined value based on a number of factors, such as the patient's medical history, the patient's tolerance to certain types of medication, the patient's prior exposure to the medication and/or the like), and/or may be dynamically calculated depending on the dose pattern, patient vital signs, and/or the like. For example, the maximum and/or minimum threshold values may be greater if a patient has a medical history that includes a greater tolerance to certain types of medications, and/or prior exposure to the medication.
To further illustrate,
For example, the tracking engine 110 may determine that the patient 140 is experiencing adverse symptoms at 12:00 PM based at least on the patient 140 attempting to trigger the delivery of one or more doses of medication from the pump 120. In response to determining that the patient 140 is experience adverse symptoms, the tracking engine 110 may be configured to adjust the dose pattern observed at the pump 120, for example, by modifying the quantity and/or frequency of the doses of medication delivered to the patient 140. Alternatively and/or additionally, the tracking engine 110 may respond to the patient 140 experiencing adverse symptoms by at least generating an electronic alert such as, for example, a push notification, a short messaging service (SMS) message, and/or the like. The electronic alert which may be sent to the client 150 associated with a medical professional in such that the medical professional may assess the patient 140 and/or adjust the dose pattern observed at the pump 120, for example, by modifying the quantity and/or frequency of the doses of medication delivered to the patient 140. The electronic alerts may be especially useful in some circumstances, such as when the patient 140 experiences no or limited improvement in pain level, even after the dose pattern is adjusted, and/or the patient continues to attempt to trigger the delivery of one or more doses of medication from the pump 120.
In some example embodiments, the tracking engine 110 may be configured to determine a correlation between the dose pattern observed at the pump 120 and the vital signs of the patient 140. To further illustrate,
Meanwhile, the graphs shown in
As noted, the patient 140 may be denied the delivery of a dose of medication during a lockout period at the pump 120. To prevent an excessive volume of medication (through frequency of doses being delivered) from being delivered to the patient 140, the pump 120 may undergo a lockout period subsequent to the delivery of one or more doses of medication to the patient 140. To further illustrate,
At 402, the tracking system 100 may determine, based at least on one or more dose events at the pump 120, a dose pattern at the pump 120 for delivering a medication to a patient. In some example embodiments, the dose controller 125 at the pump 120 may detect and report, to the tracking engine 110, one or more dose events at the pump 120 including, for example, the patient 140 attempting to trigger the delivery of a dose of medication, the delivery of a dose of medication to the patient 140, the denial of the delivery of a dose of medication to the patient 140, and/or the like. The tracking engine 110 may determine, based at least on the one or more dose events at the pump 120, a dose pattern at the pump 120 which may include, for example, a quantity and/or frequency of attempts to trigger the delivery of a dose of medication, the delivery of a dose of medication to the patient 140, and/or the denial of the delivery of a dose of medication to the patient 140.
At 404, the tracking system 100 may receive, from the patient monitor 130, one or more vital signs associated with the patient. In some example embodiments, the first sensor 135a and/or the second sensor 135b may be configured to measure and report, to the tracking engine 110, one or more vital signs associated with the patient 140 including, for example, respiratory rate, oxygen saturation, heart rate, pain level, motor movement, and/or the like.
At 406, the tracking engine 110 may adjust, based at least on the dose pattern at the pump 120 and the one or more vital signs associated with the patient, the dose pattern at the pump 120. In some example embodiments, the tracking engine 110 may be configured to adjust, based on the dose pattern observed at the pump 120 and/or the vital signs of the patient 140 reported by the patient monitor 130, the dose pattern at the pump 120. For example, the tracking engine 110 may adjust the dose pattern at the pump 120 by at least modifying the quantity and/or frequency of the doses of medication delivered to the patient 140. The quantity and/or frequency of the doses of medication delivered to and/or denied from the patient 140 may be modified by at least changing a duration of an active period, an inactive period, and/or lockout period implemented at the pump 120.
At 408, the tracking system 100 may generate and send, to the client 150, an electronic alert in response to detecting one or more anomalies in the dose pattern at the pump 120 and/or the one or more vital signs associated with the patient. In some example embodiments, the tracking engine 110 may be configured to track the one or more vital signs associated with the patient 140 along with the corresponding dose pattern observed at the pump 120. For example, the tracking engine 110 may correlate the one or more vital signs associated with the patient 140 with the dose pattern observed at the pump 120. Moreover, when the tracking engine 110 detect one or more anomalies in the dose pattern at the pump 120 and/or the one or more vital signs associated with the patient 140, the tracking engine 110 may generate and send, to the client 150 associated with a medical professional, an electronic alert (e.g., a push notification, a short messaging service (SMS) message, and/or the like). The one or more anomalies may include the volume of medication (e.g., dose of medication) delivered to the patient 140 being greater than a maximum threshold value and/or less than a minimum threshold value. Alternatively and/or additionally, the one or more anomalies may include one or more vital signs of the patient 140 being greater than a maximum threshold value and/or less than a minimum threshold value. The electronic alert may be sent to the client 150 such that the medical professional associated with the client 150 may assess the patient 140 and/or adjust the dose pattern observed at the pump 120, for example, by modifying the quantity and/or frequency of the doses of medication delivered to the patient 140.
As shown in
As used herein a “user interface” (also referred to as an interactive user interface, a graphical user interface or a UI) may refer to a network based interface including data fields and/or other control elements for receiving input signals or providing electronic information and/or for providing information to the user in response to any received input signals. Control elements may include dials, buttons, icons, selectable areas, or other perceivable indicia presented via the UI that, when interacted with (e.g., clicked, touched, selected, etc.), initiates an exchange of data for the device presenting the UI. A UI may be implemented in whole or in part using technologies such as hyper-text mark-up language (HTML), FLASH™, JAVA™, .NET™, web services, or rich site summary (RSS). In some implementations, a UI may be included in a stand-alone client (for example, thick client, fat client) configured to communicate (e.g., send or receive data) in accordance with one or more of the aspects described. The communication may be to or from a medical device, diagnostic device, monitoring device, or server in communication therewith.
The memory 520 is a computer readable medium such as volatile or non-volatile that stores information within the computing system 500. The memory 520 can store data structures representing configuration object databases, for example. The storage device 530 is capable of providing persistent storage for the computing system 500. The storage device 530 can be a floppy disk device, a hard disk device, an optical disk device, or a tape device, or other suitable persistent storage means. The input/output device 540 provides input/output operations for the computing system 500. In some example embodiments, the input/output device 540 includes a keyboard and/or pointing device. In various implementations, the input/output device 540 includes a display unit for displaying graphical user interfaces.
According to some example embodiments, the input/output device 540 can provide input/output operations for a network device. For example, the input/output device 540 can include Ethernet ports or other networking ports to communicate with one or more wired and/or wireless networks (e.g., a local area network (LAN), a wide area network (WAN), the Internet).
In some example embodiments, the computing system 500 can be used to execute various interactive computer software applications that can be used for organization, analysis and/or storage of data in various formats. Alternatively, the computing system 500 can be used to execute any type of software applications. These applications can be used to perform various functionalities, e.g., planning functionalities (e.g., generating, managing, editing of spreadsheet documents, word processing documents, and/or any other objects, etc.), computing functionalities, communications functionalities, etc. The applications can include various add-in functionalities or can be standalone computing products and/or functionalities. Upon activation within the applications, the functionalities can be used to generate the user interface provided via the input/output device 540. The user interface can be generated and presented to a user by the computing system 500 (e.g., on a computer screen monitor, etc.).
In some example embodiments, the pump 120 may be part of a patient care system 20 shown in
Fluid supplies 38, 40, 42, and 44, which may take various forms but in this case are shown as bottles, are inverted and suspended above the pumps. Fluid supplies may also take the form of bags, syringes, or other types of containers. Both the patient care system 20 and the fluid supplies 38, 40, 42, and 44 are mounted to a roller stand or intravenous (IV) pole 46.
A separate pump 120, 24, 26, and 28 may be used to infuse each of the fluids of the fluid supplies into the patient. The pumps 120, 24, 26, and 28 may be flow control devices that will act on the respective fluid line to move the fluid from the fluid supply through the fluid line to the patient 48. Because individual pumps are used, each can be individually set to the pumping or operating parameters required for infusing the particular medical fluid from the respective fluid supply into the patient at the particular rate prescribed for that fluid by the physician. Such medical fluids may comprise drugs or nutrients or other fluids.
Typically, medical fluid administration sets have more parts than are shown in
Referring now to
In the embodiment shown, a programming module 60 is attached to the left side of the pump 120. Other devices or modules, including another pump, may be attached to the right side of the pump 120, as shown in
The programming module 60 includes a display 62 for visually communicating various information, such as the operating parameters of the pump 120 and alert indications and alarm messages. The programming module 60 may also include a speaker to provide audible alarms. The programming module or any other module also has various input devices in this embodiment, including control keys 64 and a bar code or other scanner or reader for scanning information from an electronic data tag relating to the infusion, the patient, the care giver, or other. The programming module also has a communications system (not shown) with which it may communicate with external equipment such as a medical facility server or other computer and with a portable processor, such as a handheld portable digital assistant (“PDA), or a laptop-type of computer, or other information device that a care giver may have to transfer information as well as to download drug libraries to a programming module or pump. In some implementations, the pump 120 may provide data, such as the vital signs, to the programming module 60, which, in turn, may determine a dose pattern, detect one or more anomalies and/or cause transmission of electronic alerts associated with detected anomalies. In such implementations, the programming module 60 may communicate with the tracking engine 110, include the tracking engine 110, or implement features of the tracking engine 110 described herein.
The communications system may take the form of a radio frequency (“RF”) (radio frequency) system, an optical system such as infrared, a Blue Tooth system, or other wired or wireless system. The bar code scanner and communications system may alternatively be included integrally with the pump 120, such as in cases where a programming module is not used, or in addition to one with the programming module. Further, information input devices need not be hard-wired to medical instruments, information may be transferred through a wireless connection as well.
Turning now to
The type of pumping mechanism may vary and may be for example, a multiple finger pumping mechanism. For example, the pumping mechanism may be of the “four finger” type and includes an upstream occluding finger 72, a primary pumping finger 74, a downstream occluding finger 76, and a secondary pumping finger 78. The “four finger” pumping mechanism and mechanisms used in other linear peristaltic pumps operate by sequentially pressing on a segment of the fluid conduit by means of the cam-following pumping fingers and valve fingers 72, 74, 76, and 78. The pressure is applied in sequential locations of the conduit, beginning at the upstream end of the pumping mechanism and working toward the downstream end. At least one finger is always pressing hard enough to occlude the conduit. As a practical matter, one finger does not retract from occluding the tubing until the next one in sequence has already occluded the tubing; thus at no time is there a direct fluid path from the fluid supply to the patient. The operation of peristaltic pumps including four finger pumps is well known to those skilled in the art and no further operational details are provided here.
In this particular embodiment,
With reference still to
Some implementations shown discuss features in relation to a pump. It will be understood that the features may be implemented in whole or in part using other medication dispensing devices such as an automated dispensing device, a robotically controlled delivery machine, or the like configured to provide medications or other substances for administration to a user.
One or more aspects or features of the subject matter described herein can be realized in digital electronic circuitry, integrated circuitry, specially designed ASICs, field programmable gate arrays (FPGAs) computer hardware, firmware, software, and/or combinations thereof. These various aspects or features can include implementation in one or more computer programs that are executable and/or interpretable on a programmable system including at least one programmable processor, which can be special or general purpose, coupled to receive data and instructions from, and to transmit data and instructions to, a storage system, at least one input device, and at least one output device. The programmable system or computing system may include clients and servers. A client and server are generally remote from each other and typically interact through a communication network. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.
These computer programs, which can also be referred to as programs, software, software applications, applications, components, or code, include machine instructions for a programmable processor, and can be implemented in a high-level procedural and/or object-oriented programming language, and/or in assembly/machine language. As used herein, the term “machine-readable medium” refers to any computer program product, apparatus and/or device, such as for example magnetic discs, optical disks, memory, and Programmable Logic Devices (PLDs), used to provide machine instructions and/or data to a programmable processor, including a machine-readable medium that receives machine instructions as a machine-readable signal. The term “machine-readable signal” refers to any signal used to provide machine instructions and/or data to a programmable processor. The machine-readable medium can store such machine instructions non-transitorily, such as for example as would a non-transient solid-state memory or a magnetic hard drive or any equivalent storage medium. The machine-readable medium can alternatively or additionally store such machine instructions in a transient manner, such as for example, as would a processor cache or other random access memory associated with one or more physical processor cores.
To provide for interaction with a user, one or more aspects or features of the subject matter described herein can be implemented on a computer having a display device, such as for example a cathode ray tube (CRT) or a liquid crystal display (LCD) or a light emitting diode (LED) monitor for displaying information to the user and a keyboard and a pointing device, such as for example a mouse or a trackball, by which the user may provide input to the computer. Other kinds of devices can be used to provide for interaction with a user as well. For example, feedback provided to the user can be any form of sensory feedback, such as for example visual feedback, auditory feedback, or tactile feedback; and input from the user may be received in any form, including acoustic, speech, or tactile input. Other possible input devices include touch screens or other touch-sensitive devices such as single or multi-point resistive or capacitive track pads, voice recognition hardware and software, optical scanners, optical pointers, digital image capture devices and associated interpretation software, and the like.
In the descriptions above and in the claims, phrases such as “at least one of” or “one or more of” may occur followed by a conjunctive list of elements or features. The term “and/or” may also occur in a list of two or more elements or features. Unless otherwise implicitly or explicitly contradicted by the context in which it used, such a phrase is intended to mean any of the listed elements or features individually or any of the recited elements or features in combination with any of the other recited elements or features. For example, the phrases “at least one of A and B;” “one or more of A and B;” and “A and/or B” are each intended to mean “A alone, B alone, or A and B together.” A similar interpretation is also intended for lists including three or more items. For example, the phrases “at least one of A, B, and C;” “one or more of A, B, and C;” and “A, B, and/or C” are each intended to mean “A alone, B alone, C alone, A and B together, A and C together, B and C together, or A and B and C together.” Use of the term “based on,” above and in the claims is intended to mean, “based at least in part on,” such that an unrecited feature or element is also permissible.
As used herein, the terms “determine” or “determining” encompass a wide variety of actions. For example, “determining” may include calculating, computing, processing, deriving, generating, obtaining, looking up (e.g., looking up in a table, a database or another data structure), ascertaining and the like via a hardware element without user intervention. Also, “determining” may include receiving (e.g., receiving information), accessing (e.g., accessing data in a memory) and the like via a hardware element without user intervention. “Determining” may include resolving, selecting, choosing, establishing, and the like via a hardware element without user intervention.
As used herein, the terms “provide” or “providing” encompass a wide variety of actions. For example, “providing” may include storing a value in a location of a storage device for subsequent retrieval, transmitting a value directly to the recipient via at least one wired or wireless communication medium, transmitting or storing a reference to a value, and the like. “Providing” may also include encoding, decoding, encrypting, decrypting, validating, verifying, and the like via a hardware element.
As used herein, the term “message” encompasses a wide variety of formats for communicating (e.g., transmitting or receiving) information. A message may include a machine readable aggregation of information such as an XML document, fixed field message, comma separated message, or the like. A message may, in some implementations, include a signal utilized to transmit one or more representations of the information. While recited in the singular, it will be understood that a message may be composed, transmitted, stored, received, etc. in multiple parts.
As user herein, the terms “correspond” or “corresponding” encompasses a structural, functional, quantitative and/or qualitative correlation or relationship between two or more objects, data sets, information and/or the like, preferably where the correspondence or relationship may be used to translate one or more of the two or more objects, data sets, information and/or the like so to appear to be the same or equal. Correspondence may be assessed using one or more of a threshold, a value range, fuzzy logic, pattern matching, a machine learning assessment model, or combinations thereof.
In any embodiment, data can be forwarded to a “remote” device or location,” where “remote,” means a location or device other than the location or device at which the program is executed. For example, a remote location could be another location (e.g., office, lab, etc.) in the same city, another location in a different city, another location in a different state, another location in a different country, etc. As such, when one item is indicated as being “remote” from another, what is meant is that the two items can be in the same room but separated, or at least in different rooms or different buildings, and can be at least one mile, ten miles, or at least one hundred miles apart. “Communicating” information references transmitting the data representing that information as electrical signals over a suitable communication channel (e.g., a private or public network). “Forwarding” an item refers to any means of getting that item from one location to the next, whether by physically transporting that item or otherwise (where that is possible) and includes, at least in the case of data, physically transporting a medium carrying the data or communicating the data. Examples of communicating media include radio or infra-red transmission channels as well as a network connection to another computer or networked device, and the internet or including email transmissions and information recorded on websites and the like.
The subject matter described herein can be embodied in systems, apparatus, methods, and/or articles depending on the desired configuration. The implementations set forth in the foregoing description do not represent all implementations consistent with the subject matter described herein. Instead, they are merely some examples consistent with aspects related to the described subject matter. Although a few variations have been described in detail above, other modifications or additions are possible. In particular, further features and/or variations can be provided in addition to those set forth herein. For example, the implementations described above can be directed to various combinations and subcombinations of the disclosed features and/or combinations and subcombinations of several further features disclosed above. In addition, the logic flows depicted in the accompanying figures and/or described herein do not necessarily require the particular order shown, or sequential order, to achieve desirable results. Other implementations may be within the scope of the following claims.
The present application claims priority to U.S. Provisional Application No. 62/790,876, filed on Jan. 10, 2019, and titled “SYSTEM FOR MONITORING DOSE PATTERN AND PATIENT RESPONSE,” the entirety of which is incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
4551133 | Zegers de Beyl | Nov 1985 | A |
5945651 | Chorosinski et al. | Aug 1999 | A |
5961036 | Michael et al. | Oct 1999 | A |
5991731 | Colon et al. | Nov 1999 | A |
6650964 | Spano, Jr. et al. | Nov 2003 | B2 |
6671579 | Spano, Jr. et al. | Dec 2003 | B2 |
6842736 | Brzozowski | Jan 2005 | B1 |
6868344 | Nelson | Mar 2005 | B1 |
7119689 | Mallett et al. | Oct 2006 | B2 |
7184897 | Nelson | Feb 2007 | B2 |
7275645 | Mallett et al. | Oct 2007 | B2 |
7303081 | Mallett et al. | Dec 2007 | B2 |
7311207 | Mallett et al. | Dec 2007 | B2 |
7318529 | Mallett et al. | Jan 2008 | B2 |
7562025 | Mallett et al. | Jul 2009 | B2 |
7693603 | Higham | Apr 2010 | B2 |
8147479 | Wach et al. | Apr 2012 | B1 |
8195328 | Mallett et al. | Jun 2012 | B2 |
8280550 | Levy et al. | Oct 2012 | B2 |
8319669 | Weller | Nov 2012 | B2 |
8357114 | Poutiatine et al. | Jan 2013 | B2 |
8595021 | Mallett et al. | Nov 2013 | B2 |
8606596 | Bochenko et al. | Dec 2013 | B1 |
8725532 | Ringold | May 2014 | B1 |
8738177 | Van Ooyen et al. | May 2014 | B2 |
8768724 | Whiddon et al. | Jul 2014 | B2 |
8905964 | Poutiatine et al. | Dec 2014 | B2 |
9158892 | Levy et al. | Oct 2015 | B2 |
9202052 | Fang et al. | Dec 2015 | B1 |
9227025 | Butterfield et al. | Jan 2016 | B2 |
9354178 | Lee | May 2016 | B2 |
9427520 | Batch et al. | Aug 2016 | B2 |
9456958 | Reddy et al. | Oct 2016 | B2 |
9523635 | Tilden | Dec 2016 | B2 |
9636273 | Harris | May 2017 | B1 |
9752935 | Marquardt et al. | Sep 2017 | B2 |
9796526 | Smith et al. | Oct 2017 | B2 |
9817850 | Dubbels et al. | Nov 2017 | B2 |
9836485 | Dubbels et al. | Dec 2017 | B2 |
9842196 | Utech et al. | Dec 2017 | B2 |
9881129 | Cave | Jan 2018 | B1 |
9958324 | Marquardt et al. | May 2018 | B1 |
10032344 | Nelson et al. | Jul 2018 | B2 |
10101269 | Judge et al. | Oct 2018 | B2 |
10187288 | Parker et al. | Jan 2019 | B2 |
10209176 | Proskurowski et al. | Feb 2019 | B2 |
10241038 | Nishimura et al. | Mar 2019 | B2 |
10249153 | Nelson et al. | Apr 2019 | B2 |
10309832 | Marquardt et al. | Jun 2019 | B2 |
10345242 | Zhao et al. | Jul 2019 | B2 |
10832207 | Vahlberg et al. | Nov 2020 | B2 |
11037666 | Benoit et al. | Jun 2021 | B1 |
11116892 | Brady et al. | Sep 2021 | B2 |
11147914 | Estes | Oct 2021 | B2 |
11481739 | McKinzie | Oct 2022 | B1 |
20030158751 | Suresh et al. | Aug 2003 | A1 |
20070260487 | Bartfeld et al. | Nov 2007 | A1 |
20080059226 | Melker et al. | Mar 2008 | A1 |
20080082360 | Bailey et al. | Apr 2008 | A1 |
20080140715 | Hakos | Jun 2008 | A1 |
20080243055 | Fathallah et al. | Oct 2008 | A1 |
20080288430 | Friedlander et al. | Nov 2008 | A1 |
20080306796 | Zimmerman et al. | Dec 2008 | A1 |
20080319795 | Poteet et al. | Dec 2008 | A1 |
20090083231 | Eberholst et al. | Mar 2009 | A1 |
20090160646 | Mackenzie et al. | Jun 2009 | A1 |
20100169063 | Yudkovitch et al. | Jul 2010 | A1 |
20100213250 | Mallett et al. | Aug 2010 | A1 |
20110016110 | Egi et al. | Jan 2011 | A1 |
20110082440 | Kimmo | Apr 2011 | A1 |
20110161108 | Miller et al. | Jun 2011 | A1 |
20120226447 | Nelson et al. | Sep 2012 | A1 |
20120265336 | Mallett et al. | Oct 2012 | A1 |
20120325330 | Prince et al. | Dec 2012 | A1 |
20130002429 | Johnson | Jan 2013 | A1 |
20130018356 | Prince et al. | Jan 2013 | A1 |
20130070090 | Bufalini et al. | Mar 2013 | A1 |
20130144254 | Amirouche et al. | Jun 2013 | A1 |
20130158705 | Levy et al. | Jun 2013 | A1 |
20130253291 | Dixon et al. | Sep 2013 | A1 |
20130253700 | Carson et al. | Sep 2013 | A1 |
20130262138 | Jaskela et al. | Oct 2013 | A1 |
20130282392 | Wurm | Oct 2013 | A1 |
20130325727 | MacDonell et al. | Dec 2013 | A1 |
20140074284 | Czaplewski et al. | Mar 2014 | A1 |
20140081652 | Klindworth | Mar 2014 | A1 |
20140149131 | Bear et al. | May 2014 | A1 |
20140249776 | King et al. | Sep 2014 | A1 |
20140277707 | Akdogan et al. | Sep 2014 | A1 |
20140375324 | Matsiev et al. | Dec 2014 | A1 |
20150038898 | Palmer et al. | Feb 2015 | A1 |
20150061832 | Pavlovic et al. | Mar 2015 | A1 |
20150081324 | Adjaoute | Mar 2015 | A1 |
20150109437 | Yang et al. | Apr 2015 | A1 |
20150161558 | Gitchell et al. | Jun 2015 | A1 |
20150221086 | Bertram | Aug 2015 | A1 |
20150272825 | Lim et al. | Oct 2015 | A1 |
20150286783 | Kumar et al. | Oct 2015 | A1 |
20150294079 | Bergougnan | Oct 2015 | A1 |
20150323369 | Marquardt | Nov 2015 | A1 |
20150339456 | Sprintz | Nov 2015 | A1 |
20150362350 | Miller et al. | Dec 2015 | A1 |
20160034274 | Diao et al. | Feb 2016 | A1 |
20160062371 | Davidian et al. | Mar 2016 | A1 |
20160117478 | Hanina et al. | Apr 2016 | A1 |
20160161705 | Marquardt et al. | Jun 2016 | A1 |
20160166766 | Schuster et al. | Jun 2016 | A1 |
20160259904 | Wilson | Sep 2016 | A1 |
20160259911 | Koester | Sep 2016 | A1 |
20160283691 | Ali | Sep 2016 | A1 |
20170017760 | Freese et al. | Jan 2017 | A1 |
20170032102 | Skoda | Feb 2017 | A1 |
20170076065 | Darr et al. | Mar 2017 | A1 |
20170083681 | Sprintz et al. | Mar 2017 | A1 |
20170103203 | Sharma et al. | Apr 2017 | A1 |
20170108480 | Clark et al. | Apr 2017 | A1 |
20170109480 | Vahlberg | Apr 2017 | A1 |
20170109497 | Tribble et al. | Apr 2017 | A1 |
20170120035 | Butterfield et al. | May 2017 | A1 |
20170199983 | Cano et al. | Jul 2017 | A1 |
20180028408 | Li et al. | Feb 2018 | A1 |
20180039736 | Williams | Feb 2018 | A1 |
20180046651 | Dubbels et al. | Feb 2018 | A1 |
20180157803 | Mirov | Jun 2018 | A1 |
20180165417 | Hall et al. | Jun 2018 | A1 |
20180192942 | Clark | Jul 2018 | A1 |
20180203978 | Basu | Jul 2018 | A1 |
20180231415 | Marquardt et al. | Aug 2018 | A1 |
20180247703 | D'Amato | Aug 2018 | A1 |
20180259446 | Coffey et al. | Sep 2018 | A1 |
20180299375 | Young et al. | Oct 2018 | A1 |
20180330824 | Athey et al. | Nov 2018 | A1 |
20180365385 | Cooney | Dec 2018 | A1 |
20180365386 | Vanderveen | Dec 2018 | A1 |
20190088354 | Yanowitz et al. | Mar 2019 | A1 |
20190117883 | Abrams et al. | Apr 2019 | A1 |
20190124118 | Swafford | Apr 2019 | A1 |
20190139638 | Keefe et al. | May 2019 | A1 |
20190180862 | Wisser et al. | Jun 2019 | A1 |
20190244699 | Loebig et al. | Aug 2019 | A1 |
20190247703 | Welde et al. | Aug 2019 | A1 |
20190341142 | Nag et al. | Nov 2019 | A1 |
20190355461 | Kumar et al. | Nov 2019 | A1 |
20200085686 | Aliakbarian et al. | Mar 2020 | A1 |
20200098474 | Vanderveen | Mar 2020 | A1 |
20200219611 | Nag et al. | Jul 2020 | A1 |
20200230316 | Guerra et al. | Jul 2020 | A1 |
20200312442 | Hairr et al. | Oct 2020 | A1 |
20200402632 | van Schelven et al. | Dec 2020 | A1 |
20210005324 | Bostic et al. | Jan 2021 | A1 |
20210133201 | Tribble et al. | May 2021 | A1 |
20210308385 | Nisha et al. | Oct 2021 | A1 |
20220093239 | Nag et al. | Mar 2022 | A1 |
Number | Date | Country |
---|---|---|
2017 279 693 | Jan 2018 | AU |
2018335288 | Aug 2023 | AU |
2636115 | Jun 2014 | CA |
2848274 | Sep 2016 | CA |
1 973 593 | Apr 2013 | EP |
1 593 076 | Oct 2019 | EP |
2016-517077 | Jun 2015 | JP |
10-2014-0129141 | Nov 2014 | KR |
WO-2006034367 | Mar 2006 | WO |
WO-2010058796 | May 2010 | WO |
WO-2011014517 | Feb 2011 | WO |
WO-2011039676 | Apr 2011 | WO |
WO-2014055925 | Apr 2014 | WO |
WO-2015187682 | Dec 2015 | WO |
WO-2019028004 | Feb 2019 | WO |
WO-2019031331 | Feb 2019 | WO |
WO-2020206154 | Oct 2020 | WO |
Entry |
---|
Qui et al. (2016) “A survey of machine learning for big data processing.” EURASIP Journal on Advances in Signal Processing, Article No. 67, 16 pages. |
Yang, J., McAuley, J.J., & Leskovec, J. (2013). “Community Detection in Networks with Node Attributes.” 2013 IEEE 13th International Conference on Data Mining, 1151-1156. |
Benjamin, X.C. et al. (2012). “Visual identification of medicine boxes using features matching.” IEEE International Conference on Virtual Environments Human-Computer Interfaces and Measurement Systems(VECIMS) Proceedings, 43-47. Doi: 10.1109/VECIMS.2012.6273190. |
Cakaloglu, T. (Nov. 1, 2017). “Medi-Deep: Deep control in a medication usage.” 2017 IEEE International Conference of Bioinfomratice and Biomedicine(BIBM), 899-904. Doi: 10.1109/BIBM.2017.8217776. |
Neuman, M.R. et al. (May 13, 2012), “Advances in Medical Devices and Medical Electronics,” in Proceedings of the IEEE, vol. 100, No. Special Centennial Issue, pp. 1537-1550,doi: 10.1109/JPROC.2012.2190684. |
Shishvan, O. Rajabi et al. (2018). “Machine Intelligence in Healthcare and Medical Cyber Physical Systems: A Survey.” IEEE Access. vol. 6, 46419-46494. doi: 10.1109/ACCESS.2018.2866049. |
Uniyal, D. et al. (Nov. 7, 2014), “Pervasive Healthcare—A Comprehensive Survey of Tools and Techniques,” arXiv:1411.1821v1, 48 pages. |
Yaniv, Z. et al. (Oct. 1, 2016). “The National Library of Medicine Pill Image Recognition Challenge: An Initial Report.” Oct. 2016 IEEE Applied Imagery Pattern Recognition Workshop, (AIPR), 1-9. Doi: 10.1109/AIPR.2016.8010584. |
Zhan, A. et al. (Jan. 5, 2016) “High Frequency Remote Monitoring of Parkinson's Disease via Smartphone: Platform Overview and Medication Response Detection,” Retrieved Apr. 29, 2021. 12 pages. |
Number | Date | Country | |
---|---|---|---|
20200222627 A1 | Jul 2020 | US |
Number | Date | Country | |
---|---|---|---|
62790876 | Jan 2019 | US |